# Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study

> **NCT00191724** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 47 (actual)

## Conditions studied

- Submassive Pulmonary Embolism

## Interventions

- **DRUG:** Drotrecogin Alfa (Activated)
- **DRUG:** Enoxaparin
- **DRUG:** Placebo
- **DRUG:** Drotrecogin Alfa (Activated)
- **DRUG:** Drotrecogin Alfa (Activated)
- **DRUG:** Drotrecogin Alfa (Activated)

## Key facts

- **NCT ID:** NCT00191724
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2009-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191724, "Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00191724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*